# EDGAR Filing Document

**Accession Number:** 0001505497
**File Stem:** 0001021771-26-000058
**Filing Date:** 2026-4
**Character Count:** 7495
**Document Hash:** 720ebd7ace449a6eba8cf0c0e320ef65
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001021771-26-000058.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0001021771-26-000058

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 49

**CONFORMED PERIOD OF REPORT**: 20260423

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioRestorative Therapies, Inc.
- **CENTRAL INDEX KEY:** 0001505497
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 301341024
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37603
- **FILM NUMBER:** 26889697

**BUSINESS ADDRESS:**
- **STREET 1:** 40 MARCUS DRIVE
- **CITY:** MELVILLE
- **STATE:** NY
- **ZIP:** 11747
- **BUSINESS PHONE:** (631) 760-8100

**MAIL ADDRESS:**
- **STREET 1:** 40 MARCUS DRIVE
- **CITY:** MELVILLE
- **STATE:** NY
- **ZIP:** 11747

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stem Cell Assurance, Inc.
- **DATE OF NAME CHANGE:** 20101110

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

<u>___________________</u>

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report: April 23, 2026

(Date of earliest event reported)

<u>BIORESTORATIVE THERAPIES, INC.</u>

(Exact Name of Registrant as Specified in Charter)

<u>Nevada</u> <u>001-37603</u> <u>30-1341024</u> <br> (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification Number)

<u> 40 Marcus Drive, Melville, New York </u> <u> &nbsp;&nbsp;&nbsp;&nbsp;11747 </u> <br> (Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: <u>(631) 760-8100</u>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| | |
|:---|:---|
| &nbsp;&nbsp; ___  | &nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) <br>|
| &nbsp;&nbsp; ___  | &nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) <br>|
| &nbsp;&nbsp; ___  | &nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) <br>|
| &nbsp;&nbsp; ___  | &nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
|  <br> <u>Title of each class</u>  | <br> <u>Trading Symbol(s)</u>  | <br> <u>Name of each exchange on which registered</u>  |
|  Common Stock, $0.0001 par value  | BRTX  | Nasdaq Capital Market  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ____

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___

------

---

| | |
|:---|:---|
| **Item 7.01**  | **Regulation FD Disclosure**.  |

---

On April 23, 2026, BioRestorative Therapies, Inc. (the "Company") made available an updated corporate presentation (the "Presentation") that may be used by the Company in connection with presentations at conferences and investor meetings. The Presentation can be found on the Company's website, www.biorestorative.com. The Presentation is furnished as Exhibit 99.1 hereto.

The information in the Presentation is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Presentation will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of the information in this Current Report on Form 8-K with respect to the Presentation is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Presentation is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

---

| | |
|:---|:---|
| **Item 9.01**  | **Financial Statements and Exhibits**.  |

---

(d) <u>Exhibits</u>.

---

| | |
|:---|:---|
| &nbsp;&nbsp; Number  | &nbsp;&nbsp; Description  |
| &nbsp;&nbsp; 99.1  | &nbsp;&nbsp; Presentation Materials  |
| &nbsp;&nbsp; 104  | &nbsp;&nbsp; Cover Page Interactive Data File (embedded within the Inline XBRL document)  |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| &nbsp;&nbsp; Dated: April 23, 2026  | &nbsp;&nbsp; **BIORESTORATIVE THERAPIES, INC.**  |
|  | &nbsp;&nbsp; By: <u>/s/ Robert Kristal</u>  |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Robert Kristal  |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chief Financial Officer  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

------

## Exhibit 99.1

![ex99.pdf page 1](image01.jpg)

![ex99.pdf page 2](image02.jpg)

![ex99.pdf page 3](image03.jpg)

![ex99.pdf page 4](image04.jpg)

![ex99.pdf page 5](image05.jpg)

![ex99.pdf page 6](image06.jpg)

![ex99.pdf page 7](image07.jpg)

![ex99.pdf page 8](image08.jpg)

![ex99.pdf page 9](image09.jpg)

![ex99.pdf page 10](image10.jpg)

![ex99.pdf page 11](image11.jpg)

![ex99.pdf page 12](image12.jpg)

![ex99.pdf page 13](image13.jpg)

![ex99.pdf page 14](image14.jpg)

![ex99.pdf page 15](image15.jpg)

![ex99.pdf page 16](image16.jpg)

![ex99.pdf page 17](image17.jpg)

![ex99.pdf page 18](image18.jpg)

![ex99.pdf page 19](image19.jpg)

![ex99.pdf page 20](image20.jpg)

![ex99.pdf page 21](image21.jpg)

![ex99.pdf page 22](image22.jpg)

![ex99.pdf page 23](image23.jpg)

![ex99.pdf page 24](image24.jpg)

![ex99.pdf page 25](image25.jpg)

![ex99.pdf page 26](image26.jpg)

![ex99.pdf page 27](image27.jpg)

![ex99.pdf page 28](image28.jpg)

![ex99.pdf page 29](image29.jpg)

![ex99.pdf page 30](image30.jpg)

![ex99.pdf page 31](image31.jpg)

![ex99.pdf page 32](image32.jpg)

![ex99.pdf page 33](image33.jpg)

![ex99.pdf page 34](image34.jpg)

![ex99.pdf page 35](image35.jpg)

![ex99.pdf page 36](image36.jpg)

![ex99.pdf page 37](image37.jpg)